LAVA Therapeutics BV

General Information

We are a biotechnology company focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells. Our approach activates Vg9Vd2 T cells, a specific and relatively abundant gamma-delta effector T cell subset, upon cross-linking to a selected tumor target by our bispecific gamma-delta T cell engagers, or gamma-delta bsTCEs. These cells have the natural ability to distinguish tumor cells from healthy cells by sensing certain intracellular metabolites that are enriched in cancer cells. Activated Vg9Vd2 T cells are engaged for direct tumor cell killing and, in addition, orchestrate an immunological cascade response that includes activation of innate and adaptive immune cells in the tumor microenvironment. Vg9Vd2 T cells belong to the first line of defense against cancer, with potential to elicit potent and durable responses in the clinic. Our preclinical data demonstrate that Vg9Vd2 T cell activation and killing of patient-derived tumor cells by our gamma-delta bsTCEs is potent and specific thereby providing a significant opportunity to address unmet medical needs, if approved. We expect that activation of adaptive immunity by our approach has the potential to provide durable immune responses with the potential of enhancing patient survival. We believe we are the only company developing bispecific gamma-delta T cell engaging antibodies for the treatment of cancer.

Employees: 31
Founded: 2016
Contact Information
Address Yalelaan 60 3584 CM Utrecht, the Netherlands
Phone Number +31 6 3000 3035
Web Address
View Prospectus: LAVA Therapeutics BV
Financial Information
Market Cap $380.3mil
Revenues $3.1 mil (last 12 months)
Net Income $-13.9 mil (last 12 months)
IPO Profile
Symbol LVTX
Exchange NASDAQ
Shares (millions): 6.7
Price range $15.00 - $15.00
Est. $ Volume $100.5 mil
Manager / Joint Managers J.P. Morgan/ Jefferies/ SVB Leerink
CO-Managers Kempen & Co.
Expected To Trade: 3/25/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change